Drug profile · INN
paltusotine
PALSONIFY
paltusotine (PALSONIFY) is a somatostatin receptor 2 agonist. Associated with Crinetics Pharmaceuticals Europe GmbH.
Drug details — paltusotine
- Class
- Systemic hormonal preparations (H01)
- Route
- —
- Patents
- 1
- Programs
- 8
- Data quality
- 0.89
Quick answer
paltusotine (PALSONIFY) is a somatostatin receptor 2 agonist. Associated with Crinetics Pharmaceuticals Europe GmbH.
Key facts
Mechanism of action
Somatostatin receptor 2 agonist
Primary target: Somatostatin receptor type 2
Approval history
| Authority | Status | Date |
|---|---|---|
| EMA | approved | — |
Recent coverage
Crinetics Reports $10.3M Palsonify Sales Amid 232 Enrollment Updates
Crinetics Pharmaceuticals reports $10.3M in Palsonify sales and updates on 232 enrollment forms. This article explores the implications for investors and BD teams.
Crinetics Pharmaceuticals Receives EU Approval for PALSONIFY (Paltusotine), First Oral Daily Acromegaly Treatment
Crinetics Pharmaceuticals announces European Commission approval of PALSONIFY (paltusotine), the first once-daily oral therapy for acromegaly in adults.
Pipeline programs
Related & competitor drugs
Related patents
Frequently asked questions
What is paltusotine?
paltusotine (PALSONIFY) is a somatostatin receptor 2 agonist. Associated with Crinetics Pharmaceuticals Europe GmbH.
What is the brand name for paltusotine?
PALSONIFY is a marketed brand name for paltusotine. Check FDA Drugs@FDA for the current US label holder and prescribing information.